Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name HLD-0915 + JNJ-87189401 + Pasritamig
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
HLD-0915 HLD0915|HLD 0915|JNJ-101556143 Limited information is currently available on HLD-0915, a putative AR-targeting therapy (Feb 2025).
JNJ-87189401 JNJ 87189401|JNJ87189401 CD28 Antibody 14 PSMA Antibody 24 JNJ-87189401 is a bispecific antibody that targets PSMA on tumor cells and CD28 expressed on T-cells, which potentially induces T-cell activation and tumor cell death in PSMA-expressing tumors (Ann Oncol (2024) 35 (Suppl_2): S1000; NCI Drug Dictionary).
Pasritamig JNJ78278343|JNJ 78278343|JNJ-78278343 CD3 Antibody 123 Pasritamig (JNJ-78278343) is an IgG1 bispecific antibody that targets KLK2 on tumor cells and CD3 on T-lymphocytes, which may lead to T-lymphocyte activation and killing of tumor cells expressing KLK2 (PMID: 40450573).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06095089 Phase I JNJ-87189401 + Pasritamig Apalutamide + JNJ-87189401 + Pasritamig JNJ-87189401 + lutetium Lu 177 vipivotide tetraxetan + Pasritamig HLD-0915 + JNJ-87189401 + Pasritamig A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer Recruiting USA | FRA 1


Additional content available in Icon for CKB-BoostCKB BOOST